Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111202152 | 11120215 | 2 | F | 2012 | 20160623 | 20150518 | 20160705 | EXP | US-SANOFI-AVENTIS-2013SA056284 | AVENTIS | 61.00 | YR | A | F | Y | 0.00000 | 20160705 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111202152 | 11120215 | 1 | PS | AUBAGIO | TERIFLUNOMIDE | 1 | Oral | AT NIGHT | 2G95DSA | 202992 | 14 | MG | COATED TABLET | QD | |||||
| 111202152 | 11120215 | 2 | SS | AMPYRA | DALFAMPRIDINE | 1 | Oral | STRENGTH-10 MG | 14F851 | 0 | 10 | MG | TABLET | BID | |||||
| 111202152 | 11120215 | 3 | SS | AMPYRA | DALFAMPRIDINE | 1 | Oral | STRENGTH-10 MG | 14F851 | 0 | 10 | MG | TABLET | QD | |||||
| 111202152 | 11120215 | 4 | SS | AVONEX | INTERFERON BETA-1A | 1 | ROUTE- PARENTRAL | Y | UNKNOWN | 0 | INJECTION | 1X | |||||||
| 111202152 | 11120215 | 5 | C | VITAMIN E | .ALPHA.-TOCOPHEROL | 1 | 0 | ||||||||||||
| 111202152 | 11120215 | 6 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 0 | 5000 | IU | ||||||||||
| 111202152 | 11120215 | 7 | C | ASPIRIN. | ASPIRIN | 1 | 0 | 81 | MG | ||||||||||
| 111202152 | 11120215 | 8 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | DOSE:112 QG | 0 | |||||||||||
| 111202152 | 11120215 | 9 | C | SOLU-MEDROL | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | 0 | ||||||||||||
| 111202152 | 11120215 | 10 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | 20 | MG | ||||||||||
| 111202152 | 11120215 | 11 | C | BACLOFEN. | BACLOFEN | 1 | 0 | 20 | MG | ||||||||||
| 111202152 | 11120215 | 12 | C | ROPINIROLE. | ROPINIROLE | 1 | 0 | .5 | MG | ||||||||||
| 111202152 | 11120215 | 13 | C | PRAVASTATIN. | PRAVASTATIN | 1 | 0 | 40 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 111202152 | 11120215 | 1 | Multiple sclerosis |
| 111202152 | 11120215 | 2 | Multiple sclerosis |
| 111202152 | 11120215 | 3 | Multiple sclerosis |
| 111202152 | 11120215 | 4 | Multiple sclerosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 111202152 | 11120215 | HO |
| 111202152 | 11120215 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 111202152 | 11120215 | Abnormal behaviour | |
| 111202152 | 11120215 | Alopecia | |
| 111202152 | 11120215 | Cough | |
| 111202152 | 11120215 | Diarrhoea | |
| 111202152 | 11120215 | Dyspepsia | |
| 111202152 | 11120215 | Dysphagia | |
| 111202152 | 11120215 | Hypokinesia | |
| 111202152 | 11120215 | Multiple sclerosis relapse | |
| 111202152 | 11120215 | Muscular weakness | |
| 111202152 | 11120215 | Nasal congestion | |
| 111202152 | 11120215 | Nausea | |
| 111202152 | 11120215 | Paralysis | |
| 111202152 | 11120215 | Pruritus | |
| 111202152 | 11120215 | Seasonal allergy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 111202152 | 11120215 | 1 | 20130525 | 20131024 | 0 | |
| 111202152 | 11120215 | 2 | 200505 | 0 | ||
| 111202152 | 11120215 | 3 | 2015 | 0 | ||
| 111202152 | 11120215 | 4 | 2012 | 2012 | 0 | |
| 111202152 | 11120215 | 7 | 201408 | 0 |